医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Increasing Awareness of Bone Health Will Fast-track the Osteoporosis Drugs Market in APAC Region by 2019: TechNavio

2014年12月10日 AM01:45
このエントリーをはてなブックマークに追加


 

LONDON

TechNavio has announced the publication of a new market research report on the Osteoporosis Drugs Market in APAC Region, which is expected to grow at a CAGR of 4.73 percent from 2015-2019.

According to the new report, enhanced patient and physician awareness has been leading to greater drug penetration. Additionally, institutions like the National Osteoporosis Foundation are dedicated to the prevention of osteoporosis and fractures.

“In the US, May is celebrated as National Osteoporosis Awareness and Prevention month. Such initiatives are increasing the awareness of bone health among the general population,” says Faisal Ghaus, Vice President of TechNavio.

Furthermore, the paradigm shift from antiresorptive therapies to anabolic drugs is also expected to propel the overall market growth. Treatments for osteoporosis, which haven’t evolved much in the past 20 years, will see a major overhaul with the launch of new efficacious and safe anabolic treatments.

“Three late-stage pipeline products, romosozumab, BA-058 and oral PTH have been found to be highly effective in increasing bone mineral density (BMD) by almost double the amount as compared to current treatment options,” says Ghaus.

Key Information Covered in the Report:

  • Market segmentation, size and forecast through 2019
  • Market Growth Drivers:
  • Market Challenges:
  • Market Trends:
    • Increasing Awareness of Bone Health Education
    • For a full detailed list, view our report.
  • Key Vendors:
    • Amgen Inc.
    • Eli Lilly & Co.
    • Merck & Co. Inc.
    • Novartis AG
  • Other Prominent Vendors:
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Jiangsu Hengrui Medicine
    • Pfizer

TechNavio currently has more than 3000 market research reports on a huge range of topics, including 50+ reports on the osteoporosis drugs market:

If you are interested in more information, please contact our media team at media@technavio.com.

CONTACT

TechNavio Research
Jes Ellacott
US: +1 630-333-9501
UK:
+44 208 123 1770
Media & Marketing Executive
www.technavio.com
media@technavio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Medidata宣布快速扩展其传感器云网络,再添10家卫生技术创新组织
  • ウォルグリーン・ブーツ・アライアンスが戦略的見直しを完了し、好業績のブーツ事業の所有権を保持することを決定
  • OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
  • DEXLEVO Strengthens Global Reputation of GOURI at IMCAS, the World’s Largest Beauty Anti-Aging Society
  • Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation